Research Article

Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism

Pediatric Intensive Care Department, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

^‡Authors contributed equally

Search for more papers by this author

Dominique Debray^‡

Pediatric Hepatology Department, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

^‡Authors contributed equally

Search for more papers by this author

Mikaela Kolaci

Pharmacology Department, University Paris-Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

Search for more papers by this author

Jerome Bouligand

Molecular Genetics, Pharmacogenetics & Hormonology Department, University Paris-Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

Search for more papers by this author

Valérie Furlan

Pharmacy Department, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

Search for more papers by this author

Monique Fabre

Pathology Department, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France and Pathology Department, Institute of Cancer Gustave Roussy, Villejuif, France

Search for more papers by this author

Alexia Letierce

Clinical Research Unit (URC) Paris Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

Search for more papers by this author

Céline Verstuyft

Pharmacology Department, University Paris-Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France

Search for more papers by this author

Laurent Becquemont

* Author for correspondence

Pharmacology Department, University Paris-Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France and Clinical Research Unit (URC) Paris Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, France and Clinical Research Center (CRC) Paris Sud, Assistance Publique Hôpitaux de Paris, Bicêtre Hospital, le Kremlin Bicêtre, 78, rue du Général Leclerc, Cedex, France.

Search for more papers by this author

Email the corresponding author at laurent.becquemont@bct.aphp.fr

Published Online:9 Jul 2013https://doi.org/10.2217/pgs.13.87

View article

Abstract

Aim: Little information is available regarding the influence of CYP3A5 genetic polymorphisms on tacrolimus dose requirement in pediatric liver transplantation. Patients & methods: We performed a retrospective study among 179 pediatric liver recipients grafted between 2002 and 2009 in order to determine the influence of donor CYP3A5 genotype along with clinical variables on tacrolimus daily dose requirement during the first weeks following transplantation. Results: Mean stable tacrolimus daily dose requirement was higher among children who received a liver expressing CYP3A5 (carrying the CYPA3A5*1 allele) compared with those with a liver that did not express CYP3A5 (CYP3A5*3/*3 genotype): 0.29 ± 0.20 vs 0.18 ± 0.13 mg.kg^-1.d^-1, p = 0.005, respectively. A younger recipient age and fluconazole prescription were also significantly associated with tacrolimus daily dose requirement. Time to reach stable tacrolimus therapeutic trough concentrations was prolonged among patients with a CYP3A5-expressing graft (26 vs 21 days, p = 0.04). Conclusion: Donor CYP3A5 genotype partially explains tacrolimus dose requirement.

Original submitted 30 January 2013; Revision submitted 2 May 2013

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Fouquet V, Alves A, Branchereau S et al. Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl.11(2),152–160 (2005).Crossref, Medline, Google Scholar
2 Kelly D. Safety and efficacy of tacrolimus in pediatric liver recipients. Pediatr. Transplant.15(1),19–24 (2010).Crossref, Medline, Google Scholar
3 Kelly D, Jara P, Rodeck B et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet364(9439),1054–1061 (2004).▪▪ Clinical evidence of the benefit of tacrolimus in pediatric liver transplantation.Crossref, Medline, CAS, Google Scholar
4 Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol.14(7),1889–1896 (2003).Crossref, Medline, CAS, Google Scholar
5 Fukudo M, Yano S, Masuda S et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther.80,331–345 (2006).Crossref, Medline, CAS, Google Scholar
6 Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to cyp3a5 and mdr1 gene polymorphisms. Am. J. Transplant.3(4),477–483 (2003).Crossref, Medline, CAS, Google Scholar
7 Zhao W, Elie V, Roussey G et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther.86(6),609–618 (2009).Crossref, Medline, CAS, Google Scholar
8 Goto M, Masuda S, Kiuchi T et al.CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14(7),471–478 (2004).Crossref, Medline, CAS, Google Scholar
9 Wei-Lin W, Jing J, Shu-Sen Z et al. Tacrolimus dose requirement in relation to donor and recipient abcb1 and CYP3A5 gene polymorphisms in chinese liver transplant patients. Liver Transpl.12,775–780 (2006).Crossref, Medline, Google Scholar
10 Masuda S, Goto M, Fukatsu S et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther.79,90–102 (2006).Crossref, Medline, CAS, Google Scholar
11 Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet.27(4),383–391 (2001).▪▪ First explanation of CYP3A5 expressor status.Crossref, Medline, CAS, Google Scholar
12 Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther.87(6),721–726 (2010).▪▪ Unique randomized controlled trial to demonstrate the benefit of a pharmacogenetic-based tacrolimus prescription.Medline, CAS, Google Scholar
13 Quteineh L, Verstuyft C. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr. Opin. Organ. Transplant.15,601–607 (2010).▪ Extensive review on how to prescribe calcineurin inhibitors, with a specific focus on pediatric liver transplant recipients.Crossref, Medline, Google Scholar
14 Quteineh L, Verstuyft C, Furlan V et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol.103(6),546–552 (2008).Crossref, Medline, CAS, Google Scholar
15 Briceño J, Ciria R, Pleguezuelo M et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis c virus cirrhosis. Liver Transpl.15,37–48 (2009).Crossref, Medline, Google Scholar
16 Koçbiyik A, Demirhan B, Sevmis S, Budakoglu I, Karakayali H, Haberal M. Role of postreperfusion subcapsular wedge biopsies in predicting initially poor graft function after liver transplantation. Transplant. Proc.41,2747–2748 (2009).Crossref, Medline, CAS, Google Scholar
17 Busquets J, Figueras J, Serrano T et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl.7,432–435 (2001).Crossref, Medline, CAS, Google Scholar
18 Kakizoe S, Yanaga K, Starzl T, Demetris A. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology11,932–941 (1990).Crossref, Medline, CAS, Google Scholar
19 Ferraris J, Argibay P, Costa L et al. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr. Transplant.15,525–532 (2011).Crossref, Medline, CAS, Google Scholar
20 Gijsen V, Mital S, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant.30(12),1352–1359 (2011).Crossref, Medline, Google Scholar
21 Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther.82(6),711–725 (2007).Crossref, Medline, CAS, Google Scholar
22 de Wildt SN, van Schaik RH, Soldin OP et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol.67(12),1231–1241 (2011).Crossref, Medline, Google Scholar
23 Yu S, Wu L, Jin J et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation81(1),46–51 (2006).Crossref, Medline, CAS, Google Scholar
24 Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM. Combinational effect of intestinal and hepatic cyp3a5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation94(8),866–872 (2012).Crossref, Medline, CAS, Google Scholar
25 Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation85(8),1139–1145 (2008).Crossref, Medline, CAS, Google Scholar
26 Fakhoury M, Litalien C, Medard Y et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos.33(11),1603–1607 (2005).Crossref, Medline, CAS, Google Scholar
27 Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349(12),1157–1167 (2003).Crossref, Medline, CAS, Google Scholar
28 Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics18(10),861–868 (2008).Crossref, Medline, CAS, Google Scholar
29 Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of ki values and impact of CYP3A5 expression. Drug Metab. Dispos.27(2),180–187 (1999).Medline, CAS, Google Scholar
101 US FDA: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htmGoogle Scholar
102 Diflucan. www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdfGoogle Scholar

Vol. 14, No. 9

Metrics

Downloaded 307 times

History

Published online 9 July 2013

Published in print July 2013

Information

Keywords

Authors’ contribution

P Durand: conception of the study design, inclusion of patients, analysis of data and writing the paper; D Debray: conception of the study design, inclusion of patients, analysis of data and writing the paper; M Kolaci: conception of the study design, inclusion of patients, biological analysis, analysis of data and writing the paper; J Bouligand: conception of the study design, biological analysis, analysis of data and writing the paper; V Furlan: conception of the study design, inclusion of patients, biological analysis, analysis of data and writing the paper; M Fabre: conception of the study design, inclusion of patients, histological analysis of data and writing the paper; A Letierce: conception of the study design, analysis of data and writing the paper; C Piedvache: reanalysis of the study data according to reviewers suggestions; C Verstuyft: analysis of data and writing the paper; L Becquemont: conception of the study design, analysis of data, writing the paper and corresponding author.

Acknowledgements

The authors wish to acknowledge the help provided by C Piedvache for the independent and complete statistical reanalysis of the data.

Financial & competing interests disclosure

L Becquemont received consulting fees from Sanofi-Aventis, Pfizer and Servier, and lecture fees from Genzyme, GlaxoSmithKline, Bristol-Myers Squibb and Merck Sharp and Dohme. His wife works for Sanofi-Aventis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download